INTRODUCTION

In terms of microbiological contamination risk control, there are two broad categories of drug products: (a) sterile products, in which the bioburden is essentially eliminated using validated methodologies, and (b) nonsterile products for which the final product bioburden is controlled to appropriate levels based on product attributes, route of administration, and target patient population.